ST2 Values Predict Mortality and Morbidity in Heart Failure Patients: Results from the AstraZeneca-sponsored CORONA Study

ST2 Values Predict Mortality and Morbidity in Heart Failure Patients: Results from the AstraZeneca-sponsored CORONA Study

SAN DIEGO, Feb 13, 2012 (BUSINESS WIRE) -- Critical Diagnostics today announced publication in the European Journal of Heart Failure of an analysis describing the prognostic power of ST2 in the CORONA study, where the investigators assessed the association between ST2 and cause-specific outcomes in 1449 clinically stable, older heart failure patients with ischemic etiology.

As the paper states, "The main finding of the current study is that in older patients with stable, systolic HF of ischemic etiology, sST2 (soluble ST2) is an independent predictor of WHF (worsening heart failure) even after adjustment for multiple variables, including NT-proBNP and C-reactive protein."

More specifically, the analysis showed ST2 to be powerfully prognostic for several clinically meaningful endpoints including worsening heart failure resulting in death or hospitalization as well as hospitalization for any cardiovascular cause. Furthermore, ST2 demonstrated a predictive ability additional to that of NT-proBNP - patients with NT-proBNP below median level had a significantly worse outcome if sST2 was above median level and in patients with NT-proBNP above median level, the risk of all-cause hospitalization, as well as hospitalization for WHF, significantly increased if sST2 was also above median. It was also reported that a decrease in ST2 concentrations over a 3-month period was associated with a decreased risk of hospitalization both for WHF and CV causes.

"In our population, sST2 was firmly associated with endpoints pertaining to progressive HF," states Dr. Lars Gullestad, Professor of Medicine at the University of Oslo and an author on the paper.

"Consistent with previous studies, the CORONA investigators have shown that the cardiac biomarker ST2 identifies heart failure patients who are at increased risk of worsening disease or death that is not detected using other available tests or clinical assessment," notes Critical Diagnostics President James Snider. "The Presage ST2 Assay is clearly a powerful new tool enabling physicians to better evaluate the disease status of their heart failure patients which should lead to improved treatment and better outcomes."

About Critical Diagnostics and ST2

Critical Diagnostics ( www.criticaldiagnostics.com ) develops novel biomarkers to help physicians optimize patient care in cardiovascular diseases, while containing healthcare costs. The Presage(R) ST2 Assay has been CE Marked and cleared by the US FDA. Critical Diagnostics has exclusive worldwide rights to ST2 for the diagnosis and prognosis of cardiovascular disease.

SOURCE: Critical Diagnostics



Critical Diagnostics
James Snider, 877-700-1250
President
[email protected]

 

 

Suggested Articles

Adimab spinout Adagio Therapeutics raised $50 million to develop antibodies that target SARS-CoV-2 and other coronaviruses.

Relay Therapeutics has pulled off a major upsized IPO worth $400 million to propel a pipeline of treatments aiming at previously undruggable targets.

The series C follows phase 1b data on the brain cancer treatment that persuaded existing investors including HP WILD to commit more cash.